The cell membrane is a double layer of fatty molecules, and cholesterol within it is not evenly distributed. Biochemists now distinguish between accessible cholesterol, which floats freely and can interact with proteins, and inaccessible cholesterol, which is locked away by phospholipids such as sphingomyelin. Using sophisticated fluorescent probes derived from bacterial toxins, researchers have learned that the outer leaflet of the membrane generally holds far more accessible cholesterol than the inner leaflet, in some cases more than ten times as much. This asymmetry matters because intracellular lipid transfer proteins, including the GRAMD family, can only pick up cholesterol that is accessible on the inner side of the membrane. If dietary cholesterol is to travel from the cell surface to the endoplasmic reticulum without being packaged into vesicles, it must somehow cross from one leaflet to the other.

Yamanashi’s team hypothesized that NPC1L1 might be the factor that makes this crossing possible. Working with McA-RH7777 liver cells engineered to express the protein, they used two complementary probes: mCherry-tagged domain 4 of perfringolysin O, which labels accessible cholesterol in the outer leaflet, and a high-affinity variant called D4H that reports on the inner leaflet. The results were striking. Cells expressing NPC1L1 showed significantly reduced outer-leaflet cholesterol signal, while the inner-leaflet signal rose. In other words, the protein appeared to redistribute cholesterol from the outside of the membrane to the inside, making it available to the cell’s internal trafficking machinery.

Crucially, both effects vanished when the cells were treated with ezetimibe, and the inhibition was concentration-dependent, becoming evident at around two micromolar and reaching near-maximal levels at ten micromolar. Ezetimibe did not alter cholesterol distribution in control cells, and it had little effect on the total amount or membrane localization of NPC1L1 itself, ruling out nonspecific disruption of the membrane. Even a short one-hour exposure to the drug was enough to reverse the redistribution, suggesting the effect is direct rather than a downstream consequence of altered protein expression. The team confirmed the inner-leaflet findings with a second, independent biosensor called GFP-GRAM-W, which also showed increased inner-leaflet cholesterol in NPC1L1-expressing cells that was suppressed by ezetimibe.

One obvious alternative explanation was that NPC1L1 might simply be changing the amount of sphingomyelin in the outer leaflet, since sphingomyelin binds cholesterol and sequesters it. The researchers tested this using a fluorescent lysenin probe that specifically labels sphingomyelin, and found no difference between NPC1L1-expressing and control cells. This means NPC1L1 is a genuinely novel regulator of cholesterol asymmetry, working independently of the sphingomyelin shield. It also places NPC1L1 in a small and exclusive club. The cholesterol efflux transporters ABCA1 and ABCG1 are known to push accessible cholesterol from the inner to the outer leaflet, but no transporter had previously been shown to do the opposite.

To dissect the mechanism, the team turned to NPC1L1’s two specialized domains. The N-terminal domain, or NTD, is an extracellular region known to bind cholesterol directly. When the researchers introduced a mutation called L216A that cripples cholesterol binding in the NTD, the mutant protein still reduced outer-leaflet cholesterol and increased inner-leaflet cholesterol just like the wild-type protein, even though its ability to take up micellar cholesterol was severely impaired. However, when cells expressing either the wild-type or the mutant protein were fed cholesterol-containing micelles, only the wild-type cells showed an increase in outer-leaflet accessible cholesterol. This suggests the NTD’s job is to capture extracellular cholesterol and insert it into the outer leaflet, a process that ezetimibe only partially blocked.

The real star of the redistribution story turned out to be the sterol-sensing domain, or SSD, a conserved transmembrane region shared with other cholesterol regulators such as NPC1, HMG-CoA reductase, and the signaling receptor Patched 1. Mutations at two key cholesterol-binding residues within the SSD, L649R and a double mutation at G652 and S653, abolished the protein’s ability to lower outer-leaflet cholesterol and raise inner-leaflet cholesterol, while leaving protein expression and membrane localization intact. Both mutations also reduced cholesterol uptake, consistent with earlier work. Cryo-electron microscopy studies have shown that the SSD contains a tunnel structure that directly binds cholesterol, and the new functional data align neatly with that structural picture: cholesterol recognition by the SSD is required for NPC1L1 to control cholesterol accessibility across the membrane.

The findings also challenge the assumption that NPC1L1 works mainly through vesicular endocytosis, the pathway in which the protein is internalized along with its cholesterol cargo. A C-terminal mutation called Y1306A, known to impair cholesterol-dependent endocytosis, redistributed accessible cholesterol across the membrane just as effectively as the wild-type protein in the researchers’ experiments. This supports an emerging model in which non-vesicular transport plays a major role in cholesterol absorption. Recent work has shown that intestinal cholesterol absorption is reduced in mice lacking GRAMD1b and GRAMD1c, proteins that shuttle cholesterol from the inner leaflet of the plasma membrane to the endoplasmic reticulum. The new study fits this model perfectly: the NTD captures and inserts extracellular cholesterol into the outer leaflet, and the SSD then increases its accessibility on the inner leaflet, where GRAMD proteins can hand it off to the endoplasmic reticulum for esterification.

The implications extend beyond the gut. The researchers examined MDA-MB-231 breast cancer cells, which naturally express NPC1L1, and found that either ezetimibe treatment or genetic knockdown of the protein increased outer-leaflet cholesterol while decreasing inner-leaflet cholesterol, mirroring the overexpression experiments. This is intriguing because ezetimibe has been reported to suppress the migration and invasion of these very cells, and NPC1L1 expression has been linked to cancer malignancy. Since membrane cholesterol asymmetry influences cell proliferation and signal transduction, NPC1L1’s newly discovered role in cancer cells could open a fresh line of investigation into how membrane lipid organization shapes disease progression.

The authors are careful to note the limitations of their approach. The D4 and D4H probes measure cholesterol accessibility rather than absolute cholesterol amounts, and because cholesterol can spontaneously flip between leaflets, the study cannot yet prove that NPC1L1 directly mediates transbilayer movement rather than altering the membrane environment. Most mechanistic work was done in overexpressing cells, though the endogenous results in MDA-MB-231 cells argue against an artifact. Validation in intestinal models such as Caco-2 cells or organoids will be needed. Even so, the study delivers a compelling two-step model of a drug target that has been studied for twenty years, revealing that ezetimibe may work not only by blocking cholesterol capture but by scrambling the sterol-sensing domain’s control of membrane cholesterol, a mechanism that could inspire the next generation of cholesterol-lowering therapies.

Subject of Research: NPC1L1-mediated regulation of accessible cholesterol distribution between plasma membrane leaflets during non-vesicular cholesterol uptake

Article Title: Dual functions of NPC1L1 for cholesterol transport: Cholesterol capture and regulation of inner-leaflet cholesterol accessibility

Article References: Yamanashi, Y., Kitani, M., Kumamaru, M., Fukaya, T., Sugita, R., & Takada, T. (2026). Dual functions of NPC1L1 for cholesterol transport: Cholesterol capture and regulation of inner-leaflet cholesterol accessibility. iScience, 29(10), Article 117625. https://doi.org/10.1016/j.isci.2026.117625

Image Credits: AI Generated

DOI: 10.1016/j.isci.2026.117625

Keywords: NPC1L1, cholesterol, ezetimibe, plasma membrane, sterol-sensing domain, cholesterol absorption, accessible cholesterol, lipid asymmetry, GRAMD1 proteins, non-vesicular transport, cardiovascular disease, iScience

The research, conducted by Hasan Zeitooni and Masoud Shams-Bakhsh at Tarbiat Modares University in Tehran together with Rosa Lozano-Durán of Eberhard Karls University Tübingen, the Max Planck Institute for Plant Breeding Research, and the GreenRobust Cluster of Excellence, was published in Virology Journal. Because PYLCV was only recently identified and assigned to the genus Pylecuvirus as the species Pylecuvirus petroselini, essentially nothing was known about how its individual proteins behave inside plant cells. The team set out to fill that gap by focusing on C4, a protein of just 85 amino acids whose biological activities and cellular distribution had remained entirely uncharacterized.

The investigation began with comparative sequence and bioinformatic analysis of the PYLCV C4 protein. Even at only 85 residues, the protein carries an impressive collection of candidate targeting features. The computational screen identified a predicted N-terminal myristoylation motif—a lipid attachment signal that in many viral and cellular proteins anchors them to membranes—a putative palmitoylation site that could reinforce membrane association, motifs potentially related to nuclear trafficking including nuclear localization signals and a nuclear export signal, and a chloroplast transit peptide that could direct the protein into plastids. Such a combination of targeting determinants in a protein this small hints at a multifaceted role during infection, consistent with the pleiotropic effects that C4 proteins from related geminiviruses exert on their hosts.

To test these predictions experimentally, the researchers turned to confocal microscopy. They fused the C4 protein to green fluorescent protein and expressed the construct in plant tissue, allowing them to track exactly where the protein accumulates within the cell. The imaging revealed that PYLCV C4–GFP localizes prominently to the plasma membrane, the boundary between the cell interior and its surroundings, and also accumulates in two additional compartments: the nucleus, where many geminivirus proteins carry out their manipulations of host gene expression and cell cycle control, and the chloroplasts, the photosynthetic organelles that are frequent targets of viral effectors.

A key experiment followed from the predicted myristoylation motif. N-myristoylation is a covalent modification in which a myristoyl lipid group is attached to a glycine residue at position two of the protein, a process that typically requires the removal of the initiator methionine and is essential for membrane anchoring. By substituting the glycine at position 2, the team created a mutant form of C4 and examined its localization. The result was striking: loss of Gly2 strongly reduced the plasma membrane association of the C4–GFP fusion and, at the same time, increased the chloroplast-associated signal. This finding supports an important role for the Gly2-containing N-terminal region in directing the protein to the cell periphery, and it suggests a competitive relationship between targeting pathways—when Gly2-dependent membrane association is disrupted, chloroplast targeting becomes more prominent. In other words, the same short protein can be routed to different destinations depending on whether its lipid modification site is intact.

Localization studies alone cannot establish pathogenicity, so the researchers next asked what happens when the protein is produced in plants at physiological relevance. They expressed PYLCV C4 from a potato virus X–based vector in Nicotiana benthamiana, a widely used experimental host in plant virology. PVX is an RNA virus whose genome can be engineered to carry additional sequences, providing a convenient system to test whether a heterologous protein induces symptoms. The outcome was dramatic. Plants expressing PYLCV C4 developed severe developmental alterations, including mosaic patterns, yellowing, leaf curling, stem deformation, and in the most extreme cases, plant death. Critically, these symptoms arose without any change in PVX RNA accumulation, demonstrating that the damage was caused by the C4 protein itself rather than by an alteration in the vector virus’s replication. This separation of protein effect from viral accumulation is a hallmark of a genuine pathogenicity determinant.

Given that many geminivirus C4 proteins function as suppressors of RNA silencing—a cornerstone of the plant antiviral immune response—the team also examined whether PYLCV C4 interferes with post-transcriptional gene silencing, or PTGS. They employed standard silencing suppression assays, monitoring both local and systemic silencing of a reporter transgene in N. benthamiana, including the well-known 16c line that carries a green fluorescent protein transgene used to visualize silencing spread. Under the conditions tested, PYLCV C4 did not behave as a strong suppressor of local or systemic PTGS. However, the researchers observed a possible delay in the spread of GFP silencing in 16c plants, leaving open the possibility that the protein has a subtle or context-dependent effect on silencing mobility rather than a robust suppressor activity of the kind seen with classic viral silencing suppressors.

The combination of results paints a picture of a compact but multifunctional protein. PYLCV C4 is a membrane-associated factor whose N-terminal lipidation motif governs its subcellular distribution, with an apparent routing switch between the plasma membrane and the chloroplasts controlled by a single glycine residue. When expressed in plants, it is sufficient to cause severe developmental perturbation on its own, echoing the symptoms associated with the natural disease. At the same time, its weak apparent activity as a silencing suppressor distinguishes it from some of its homologs in other geminivirus genera, suggesting that different C4 proteins may achieve pathogenicity through overlapping but non-identical mechanisms.

These findings carry broader implications for understanding geminivirus evolution and host manipulation. The family Geminiviridae encompasses many genera, and their C4/AC4 proteins have diversified while retaining core functions as symptom determinants. Comparative analysis across these genera, as undertaken here with a dataset of C4/AC4 and C3 protein homologs from twelve genera, helps place PYLCV within that evolutionary landscape. The discovery that a single point of lipidation—the glycine at position two—acts as a switch between membrane and chloroplast targeting offers a mechanistic handle for future studies dissecting how subcellular localization translates into developmental reprogramming. It also raises questions about which host proteins C4 engages at each destination, whether chloroplast-associated C4 contributes to the yellowing symptoms typical of the disease, and whether nuclear accumulation supports interactions with cell cycle regulators.

As the first experimental characterization of any PYLCV protein, this work establishes a framework for future mechanistic studies of how a recently emerged geminivirus interacts with its hosts. The methodology—combining comparative sequence analysis, confocal microscopy, site-directed mutagenesis, heterologous expression, and silencing assays—provides a template that can now be extended to the virus’s remaining proteins and to PYLCV’s interactions with parsley and experimental model hosts. For a pathogen family whose members continue to emerge and recombine at alarming rates, understanding the molecular toolkit of each new virus is an essential step toward anticipating and managing the diseases they cause.

Subject of Research: Functional characterization of the C4 pathogenicity protein of parsley yellow leaf curl virus

Article Title: Characterization of the C4 protein encoded by parsley yellow leaf curl virus

Article References: Zeitooni, H., Lozano-Durán, R., & Shams-Bakhsh, M. (2026). Characterization of the C4 protein encoded by parsley yellow leaf curl virus. Virology Journal. https://doi.org/10.1186/s12985-026-03309-9

Image Credits: AI Generated

DOI: 10.1186/s12985-026-03309-9

Keywords: geminivirus, PYLCV, C4 protein, myristoylation, plasma membrane, chloroplast, Nicotiana benthamiana, potato virus X, pathogenicity, gene silencing, symptom determinants, plant virology

The research team, led by Xiaodong Wu and Weidong Fei of the Women’s Hospital, Zhejiang University School of Medicine, together with corresponding authors Xiao Li, Jiale Qin and Xiaodong Cheng, set out to test a proposition that sits at the intersection of mechanobiology and cancer therapy: that the physical properties of the tumor cell plasma membrane are not passive bystanders in drug resistance but active participants, and that deliberately perturbing those properties could kill resistant cells outright. The plasma membrane, after all, is the cell’s primary sensor and transmitter of mechanical signals, and growing evidence has implicated membrane characteristics — fluidity, charge, curvature, and lipid composition — in the establishment and maintenance of the multi-drug resistant phenotype.

The technique the investigators employed combines low-intensity focused ultrasound, or LIFU, with microbubbles, an approach abbreviated LIFU-MB. Microbubbles are micron-sized gas-filled spheres that oscillate dramatically when struck by an ultrasound field. When focused ultrasound waves encounter these bubbles in the vicinity of cells, the bubbles undergo stable volumetric oscillations and acoustic radiation forces that translate into mechanical stimulation of adjacent plasma membranes. Unlike high-intensity focused ultrasound, which relies on thermal ablation and tissue destruction, LIFU operates at intensities that are largely non-thermal, making it an attractive tool for reversible, controllable mechanobiological manipulation. The question the researchers posed was deceptively simple: what happens to a paclitaxel-resistant ovarian cancer cell when its membrane is mechanically shaken in this way?

The answer, at the biophysical level, was remarkably consistent across their experiments. LIFU-MB treatment significantly decreased plasma membrane fluidity in the resistant cells, measured using the fluorescent anisotropy probe 1,6-diphenyl-1,3,5-hexatriene, whose polarization values report how tightly lipid molecules are packed. Simultaneously, the membrane potential became less negative — the membrane was depolarized. When the team probed the underlying lipid composition, they found a likely explanation: reduced levels of phosphatidylserine, the negatively charged phospholipid that normally contributes to the inner leaflet’s negative surface charge and influences the electrostatic environment that stabilizes membrane proteins. Less phosphatidylserine means a less negatively charged membrane interior surface, which alters how transmembrane proteins sit, anchor, and function within the bilayer.

That mechanistic thread led directly to one transmembrane protein in particular: SLC7A11, the solute carrier family 7 member 11, which imports cystine into the cell to fuel glutathione synthesis. SLC7A11 is a linchpin of cellular antioxidant defense and, by extension, a key guard against ferroptosis — the iron-dependent form of regulated cell death characterized by overwhelming lipid peroxidation. By disrupting the membrane’s physical and electrostatic environment, the ultrasound-triggered mechanical forces compromised the expression and function of SLC7A11. Cystine uptake faltered, intracellular glutathione levels dropped, and the antioxidant firewall weakened. Reactive oxygen species accumulated, lipid peroxidation products such as malondialdehyde and 4-hydroxynonenal rose, and the canonical ferroptotic signature — including changes in glutathione peroxidase 4 activity and prostaglandin-endoperoxide synthase 2 expression — emerged in the resistant cells.

The specificity of this death program was confirmed pharmacologically. When the researchers applied ferrostatin-1, a well-characterized ferroptosis inhibitor, the cell death induced by LIFU-MB was substantially rescued, tying the ultrasound-triggered membrane perturbation causally to the ferroptotic pathway rather than to generic necrosis or apoptosis. This matters therapeutically because ferroptosis is largely independent of the p53 status, tubulin architecture, and efflux pump dynamics that conventional chemotherapy exploits and to which resistant tumors adapt. In other words, the researchers were not trying to push resistant cells back into sensitivity to paclitaxel; they were detonating an entirely different vulnerability that the resistant phenotype had never needed to defend — until its membrane was mechanically disrupted.

The team then moved from cell culture into animal models, treating nude mice bearing paclitaxel-resistant epithelial ovarian cancer xenografts. The in vivo results were striking: tumor volumes in the LIFU-MB treatment group were significantly reduced compared with controls, and histological analysis of tumor tissue showed ferroptotic markers consistent with the in vitro findings. Equally important from a translational standpoint was the safety profile. Across systemic assessment and organ-specific histopathology — including hematoxylin and eosin staining of major organs — the investigators reported no apparent systemic or organ-specific toxicity. Because microbubbles concentrate the mechanical energy at the targeted tissue and LIFU intensities spare non-target structures, the approach retains the spatial selectivity that has made focused ultrasound a darling of interventional medicine, without the thermal collateral damage of high-intensity regimens.

What makes the study conceptually viral is its reframing of drug resistance as a biophysical weakness rather than an insurmountable biochemical fortress. Chemoresistant cells invest heavily in pumping drugs out, rewiring metabolism, and repairing DNA damage, but they cannot easily redesign the fundamental physics of their plasma membranes, which are constrained by the same lipid-handling machinery in every cell. By showing that externally applied mechanical force — no drug payload required — can depolarize the membrane, stiffen lipid packing, strip away the electrostatic support that SLC7A11 depends on, and thereby collapse the cell’s defenses against ferroptosis, the Zhejiang team has essentially demonstrated a drug-free route to killing cells that no longer respond to drugs. The finding also connects to a broader movement in mechanobiology, which increasingly treats mechanical cues — stiffness, shear, compression, and now therapeutic ultrasound — as actionable levers in oncology rather than incidental features of the tumor microenvironment.

Significant caveats remain before this strategy reaches patients. The work was performed in cell lines and xenograft-bearing mice, and the long path from preclinical promise to clinical reality will require optimization of ultrasound parameters, microbubble pharmacology, dosing schedules, and careful evaluation in orthotopic and metastatic models that better mimic human ovarian cancer’s peritoneal spread. Nevertheless, the translational infrastructure is genuinely encouraging: ultrasound is non-invasive, widely available, image-guidable, and already routine in gynecological imaging, and microbubble contrast agents have decades of clinical safety data in diagnostic use. The authors, who disclosed no competing interests and whose animal work was approved under IACUC-20220505-04 at Zhejiang Chinese Medical University, position their findings as establishing ultrasound-triggered mechanobiological forces as a potential and innovative therapeutic strategy — one that reprograms membrane biophysical properties to trigger ferroptotic cell death. For patients whose tumors have outmaneuvered every cytotoxic agent thrown at them, the idea that sound waves alone might reopen a lethal vulnerability in the cancer cell’s outer wall is more than an intriguing laboratory curiosity; it is a genuinely new front in the war against chemoresistance, and one that the oncology community will be watching closely as this work moves forward.

Subject of Research: Ultrasound-mediated mechanical perturbation of plasma membrane properties to induce ferroptosis in paclitaxel-resistant epithelial ovarian cancer cells

Article Title: Ultrasound-mediated mechanical force perturbing plasma membrane properties for paclitaxel-resistant epithelial ovarian cancer therapy

Article References: Wu, X., Fei, W., Gu, J., Fu, X., Fan, F., Liu, M., Li, X., Qin, J., & Cheng, X. (2026). Ultrasound-mediated mechanical force perturbing plasma membrane properties for paclitaxel-resistant epithelial ovarian cancer therapy. Journal of Ovarian Research. https://doi.org/10.1186/s13048-026-02260-1

Image Credits: AI Generated

DOI: 10.1186/s13048-026-02260-1

Keywords: epithelial ovarian cancer, paclitaxel resistance, low-intensity focused ultrasound, microbubbles, plasma membrane, SLC7A11, ferroptosis, mechanobiology, phosphatidylserine, membrane fluidity, Ultrasound-mediated, mechanical